Concepts (172)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Hepatocellular | 17 | 2024 | 957 | 3.060 |
Why?
|
| Liver Neoplasms | 17 | 2024 | 1386 | 2.730 |
Why?
|
| Liver Transplantation | 7 | 2023 | 1033 | 1.400 |
Why?
|
| Hepatitis C, Chronic | 5 | 2023 | 319 | 1.170 |
Why?
|
| Bile Duct Neoplasms | 3 | 2023 | 112 | 1.160 |
Why?
|
| Cholangiocarcinoma | 2 | 2023 | 110 | 0.960 |
Why?
|
| Hepatitis C | 3 | 2022 | 368 | 0.890 |
Why?
|
| Sarcopenia | 1 | 2023 | 38 | 0.860 |
Why?
|
| Famotidine | 1 | 2022 | 9 | 0.850 |
Why?
|
| Liver Diseases | 2 | 2023 | 384 | 0.820 |
Why?
|
| End Stage Liver Disease | 2 | 2023 | 178 | 0.800 |
Why?
|
| Frailty | 1 | 2023 | 98 | 0.780 |
Why?
|
| Hepatitis B, Chronic | 1 | 2022 | 84 | 0.740 |
Why?
|
| Malnutrition | 1 | 2023 | 196 | 0.740 |
Why?
|
| Hepatolenticular Degeneration | 1 | 2020 | 36 | 0.690 |
Why?
|
| Hepatitis, Alcoholic | 3 | 2024 | 23 | 0.500 |
Why?
|
| Liver Cirrhosis | 8 | 2024 | 825 | 0.440 |
Why?
|
| Esophageal and Gastric Varices | 2 | 2024 | 64 | 0.430 |
Why?
|
| Retrospective Studies | 18 | 2024 | 15853 | 0.370 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 1822 | 0.350 |
Why?
|
| Humans | 40 | 2024 | 122292 | 0.340 |
Why?
|
| Pancreatitis | 2 | 2010 | 130 | 0.330 |
Why?
|
| Antiviral Agents | 5 | 2023 | 736 | 0.330 |
Why?
|
| Risk Factors | 13 | 2024 | 9901 | 0.330 |
Why?
|
| Alcohol Drinking | 2 | 2021 | 336 | 0.320 |
Why?
|
| Fasting | 2 | 2020 | 298 | 0.320 |
Why?
|
| Bile Ducts, Intrahepatic | 3 | 2023 | 99 | 0.310 |
Why?
|
| Graft Survival | 2 | 2020 | 522 | 0.290 |
Why?
|
| Aged | 15 | 2024 | 18783 | 0.270 |
Why?
|
| Prognosis | 7 | 2024 | 4488 | 0.270 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 1118 | 0.270 |
Why?
|
| alpha-Fetoproteins | 2 | 2023 | 136 | 0.240 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2023 | 17 | 0.220 |
Why?
|
| Adult | 15 | 2024 | 28730 | 0.220 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2023 | 54 | 0.210 |
Why?
|
| Middle Aged | 20 | 2024 | 25636 | 0.210 |
Why?
|
| Hepatitis B e Antigens | 1 | 2022 | 13 | 0.200 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2022 | 15 | 0.200 |
Why?
|
| Hypertension, Portal | 1 | 2023 | 80 | 0.200 |
Why?
|
| Hemochromatosis | 1 | 2022 | 33 | 0.200 |
Why?
|
| Angiopoietin-2 | 1 | 2022 | 13 | 0.200 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2022 | 54 | 0.200 |
Why?
|
| Acute-On-Chronic Liver Failure | 1 | 2023 | 63 | 0.200 |
Why?
|
| Dietary Exposure | 1 | 2021 | 1 | 0.200 |
Why?
|
| Nitroso Compounds | 1 | 2021 | 8 | 0.200 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2021 | 16 | 0.190 |
Why?
|
| Treatment Outcome | 7 | 2023 | 12043 | 0.190 |
Why?
|
| Diet, Western | 1 | 2021 | 17 | 0.190 |
Why?
|
| United States | 8 | 2024 | 10487 | 0.190 |
Why?
|
| Diet Surveys | 1 | 2021 | 95 | 0.190 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2022 | 118 | 0.190 |
Why?
|
| Hepatitis B virus | 1 | 2022 | 142 | 0.190 |
Why?
|
| Male | 19 | 2024 | 59517 | 0.190 |
Why?
|
| Radiography | 1 | 2023 | 804 | 0.180 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 227 | 0.180 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2021 | 57 | 0.180 |
Why?
|
| Hepatitis | 1 | 2021 | 65 | 0.180 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2021 | 69 | 0.180 |
Why?
|
| Embolization, Therapeutic | 1 | 2023 | 225 | 0.180 |
Why?
|
| DNA, Viral | 1 | 2022 | 492 | 0.180 |
Why?
|
| Cause of Death | 1 | 2022 | 451 | 0.180 |
Why?
|
| Case-Control Studies | 6 | 2024 | 3229 | 0.180 |
Why?
|
| Steroids | 1 | 2021 | 203 | 0.170 |
Why?
|
| Hepatitis B | 1 | 2021 | 162 | 0.170 |
Why?
|
| Dietary Fats | 1 | 2021 | 288 | 0.170 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2019 | 23 | 0.170 |
Why?
|
| Biomarkers | 3 | 2022 | 2933 | 0.170 |
Why?
|
| Circadian Clocks | 1 | 2020 | 60 | 0.160 |
Why?
|
| Vegetables | 1 | 2021 | 257 | 0.160 |
Why?
|
| Proteome | 1 | 2020 | 234 | 0.160 |
Why?
|
| Liver | 2 | 2017 | 1851 | 0.160 |
Why?
|
| Time Factors | 4 | 2021 | 6181 | 0.160 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2021 | 387 | 0.150 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2020 | 468 | 0.150 |
Why?
|
| Severity of Illness Index | 5 | 2024 | 2817 | 0.150 |
Why?
|
| Female | 18 | 2024 | 64882 | 0.140 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2017 | 42 | 0.140 |
Why?
|
| Metabolic Syndrome | 1 | 2020 | 323 | 0.140 |
Why?
|
| Acute Kidney Injury | 1 | 2024 | 606 | 0.140 |
Why?
|
| Tissue Donors | 1 | 2020 | 498 | 0.140 |
Why?
|
| Genome-Wide Association Study | 1 | 2024 | 1630 | 0.140 |
Why?
|
| Risk Assessment | 6 | 2024 | 3307 | 0.140 |
Why?
|
| Kidney | 2 | 2017 | 1340 | 0.130 |
Why?
|
| Endoscopy, Digestive System | 2 | 2024 | 154 | 0.120 |
Why?
|
| Metabolomics | 1 | 2017 | 389 | 0.120 |
Why?
|
| Biomarkers, Tumor | 1 | 2022 | 1424 | 0.120 |
Why?
|
| Diet | 1 | 2021 | 1106 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2024 | 3050 | 0.110 |
Why?
|
| Obesity | 2 | 2023 | 2083 | 0.110 |
Why?
|
| Prospective Studies | 2 | 2022 | 5962 | 0.100 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2014 | 340 | 0.100 |
Why?
|
| Proportional Hazards Models | 3 | 2022 | 1298 | 0.100 |
Why?
|
| Sustained Virologic Response | 2 | 2023 | 41 | 0.090 |
Why?
|
| North America | 2 | 2024 | 234 | 0.090 |
Why?
|
| Hepacivirus | 2 | 2023 | 242 | 0.090 |
Why?
|
| Midazolam | 1 | 2010 | 49 | 0.090 |
Why?
|
| Fentanyl | 1 | 2010 | 43 | 0.090 |
Why?
|
| Propofol | 1 | 2010 | 44 | 0.090 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2010 | 80 | 0.080 |
Why?
|
| Hypnotics and Sedatives | 1 | 2010 | 134 | 0.080 |
Why?
|
| Cohort Studies | 4 | 2024 | 4643 | 0.080 |
Why?
|
| Pancreatic Pseudocyst | 1 | 2008 | 13 | 0.080 |
Why?
|
| Fascioliasis | 1 | 2007 | 6 | 0.070 |
Why?
|
| Fasciola hepatica | 1 | 2007 | 6 | 0.070 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2007 | 18 | 0.070 |
Why?
|
| Catheterization | 1 | 2008 | 238 | 0.070 |
Why?
|
| Drainage | 1 | 2008 | 254 | 0.070 |
Why?
|
| Rectal Diseases | 1 | 2006 | 18 | 0.070 |
Why?
|
| Pancreas | 1 | 2007 | 214 | 0.060 |
Why?
|
| Acute Disease | 1 | 2007 | 1090 | 0.060 |
Why?
|
| Intestinal Neoplasms | 1 | 2003 | 40 | 0.050 |
Why?
|
| Renal Replacement Therapy | 1 | 2024 | 141 | 0.050 |
Why?
|
| Gastric Mucosa | 1 | 2006 | 480 | 0.050 |
Why?
|
| Celiac Disease | 1 | 2003 | 70 | 0.050 |
Why?
|
| Genetic Loci | 1 | 2024 | 334 | 0.050 |
Why?
|
| Incidence | 2 | 2021 | 3018 | 0.050 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2021 | 23 | 0.050 |
Why?
|
| Health Care Rationing | 1 | 2021 | 58 | 0.050 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2023 | 220 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2020 | 337 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2021 | 239 | 0.040 |
Why?
|
| Child | 1 | 2020 | 24063 | 0.040 |
Why?
|
| Waiting Lists | 1 | 2021 | 220 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2020 | 130 | 0.040 |
Why?
|
| Protective Factors | 1 | 2019 | 82 | 0.040 |
Why?
|
| Immune System | 1 | 2020 | 86 | 0.040 |
Why?
|
| Adiposity | 1 | 2020 | 181 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2024 | 2080 | 0.040 |
Why?
|
| Cytoskeleton | 1 | 2020 | 178 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 225 | 0.040 |
Why?
|
| Attitude | 1 | 2019 | 119 | 0.040 |
Why?
|
| Life Style | 1 | 2021 | 394 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2017 | 1468 | 0.040 |
Why?
|
| Canada | 1 | 2019 | 294 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2021 | 1234 | 0.040 |
Why?
|
| Algorithms | 1 | 2024 | 1575 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2022 | 1158 | 0.040 |
Why?
|
| Lipid Metabolism | 1 | 2020 | 353 | 0.030 |
Why?
|
| DNA Repair | 1 | 2020 | 583 | 0.030 |
Why?
|
| Proteomics | 1 | 2020 | 475 | 0.030 |
Why?
|
| Logistic Models | 1 | 2021 | 1772 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 1362 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2003 | 1001 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2020 | 798 | 0.030 |
Why?
|
| Glucose | 1 | 2020 | 875 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2024 | 2573 | 0.030 |
Why?
|
| Cognition | 1 | 2020 | 732 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2017 | 480 | 0.030 |
Why?
|
| Inflammation | 1 | 2020 | 1392 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 812 | 0.030 |
Why?
|
| Adolescent | 3 | 2020 | 18939 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 1008 | 0.020 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2010 | 121 | 0.020 |
Why?
|
| Equipment Safety | 1 | 2008 | 37 | 0.020 |
Why?
|
| Infant | 1 | 2023 | 12302 | 0.020 |
Why?
|
| Endosonography | 1 | 2008 | 82 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2797 | 0.020 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2008 | 193 | 0.020 |
Why?
|
| Equipment Design | 1 | 2008 | 596 | 0.020 |
Why?
|
| Choristoma | 1 | 2006 | 49 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2010 | 6289 | 0.020 |
Why?
|
| Smoking | 1 | 2010 | 1028 | 0.010 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2006 | 240 | 0.010 |
Why?
|
| Animals | 2 | 2020 | 33723 | 0.010 |
Why?
|
| Mice | 1 | 2020 | 17548 | 0.010 |
Why?
|
| United Kingdom | 1 | 2003 | 189 | 0.010 |
Why?
|
| Health Surveys | 1 | 2003 | 235 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2003 | 298 | 0.010 |
Why?
|
| Precancerous Conditions | 1 | 2003 | 287 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2008 | 5013 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2007 | 2030 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 3448 | 0.010 |
Why?
|